Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BAY 3670549 in adults with atrial fibrillation undergoing cardioversion
2025-523807-31-00Phase 2Authorised
- Sponsor
- Bayer
- Start
- Aug 2026
- Modality
- Small Molecules
- Countries
- 8
01
Overview
Phase 2, randomised, double-blind trial in Atrial fibrillation (AFib) comparing BAY 3670549 with Placebo (2 arms). Primary endpoint: Conversion from atrial fibrillation to sinus rhythm within 3 hours. Planned start Aug 2026; status: authorised.
02
Drugs
BAY-3670549
03
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on 2025-523807-31-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-523807-31-00.